BioPETsurv: methodology and open source software to evaluate biomarkers for prognostic enrichment of time-to-event clinical trials

journal article published in 2020

BioPETsurv: methodology and open source software to evaluate biomarkers for prognostic enrichment of time-to-event clinical trials is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1371/JOURNAL.PONE.0239486
P2880NIOSHTIC-2 ID20061419
P698PubMed publication ID32946505

P50authorKathleen F. KerrQ76350439
Heather R Thiessen-PhilbrookQ87854824
Chirag R ParikhQ88232060
P2093author name stringSteven G Coca
Si Cheng
P2860cites workPredictive biomarkers for treatment selection: statistical considerationsQ26778367
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseQ29037884
Time-dependent ROC curves for censored survival data and a diagnostic markerQ30600327
The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methodsQ30988337
Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialQ33677904
Prognostic and Predictive Values and Statistical Interactions in the Era of Targeted TreatmentQ36667846
Validation of pharmacogenomic biomarker classifiers for treatment selection.Q36693782
Application of new acute kidney injury biomarkers in human randomized controlled trialsQ36909005
Enrichment of Clinical Study PopulationsQ37800007
Evaluating biomarkers for prognostic enrichment of clinical trialsQ38399183
Strategies to design clinical studies to identify predictive biomarkers in cancer research.Q38770451
Sample-size formula for the proportional-hazards regression modelQ47253781
Development of predictive signatures for treatment selection in precision medicine with survival outcomesQ47568882
Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variantsQ52568967
Biomarkers of AKI Progression after Pediatric Cardiac Surgery.Q52689194
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subsetQ56528613
An approach to evaluating and comparing biomarkers for patient treatment selectionQ87595272
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trialQ90066163
Prognostic and predictive enrichment in sepsisQ90069519
Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the PRESERVE TrialQ90236917
C-Reactive Protein Levels and the Risk of Incident Cardiovascular and Cerebrovascular Events in Patients with Obstructive Sleep ApneaQ92027431
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal CancerQ92193162
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P4510describes a project that usesggplot2Q326489
P6195funding schemecooperative agreementQ123357126
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectbiomarkerQ864574
open-source softwareQ1130645
P5008on focus list of Wikimedia projectWikimedia–NIOSH collaborationQ104416361
P304page(s)e0239486
P12526performing organizationIcahn School of Medicine at Mount SinaiQ1950740
P577publication date2020-09-18
P1433published inPLOS OneQ564954
P859sponsorNational Institute for Occupational Safety and HealthQ60346
P1476titleBioPETsurv: Methodology and open source software to evaluate biomarkers for prognostic enrichment of time-to-event clinical trials
BioPETsurv: methodology and open source software to evaluate biomarkers for prognostic enrichment of time-to-event clinical trials
P478volume15

Reverse relations

Q104129759Biomarkers of inflammation and repair in kidney disease progressioncites workP2860

Search more.